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Abstract
Background:  Current anti-AIDS therapeutic agents and treatment regimens can provide a
dramatically improved quality of life for HIV-positive people, many of whom have no detectable
viral load for prolonged periods of time. Despite this, curing AIDS remains an elusive goal, partially
due to the occurrence of drug resistance. Since the development of resistance is linked to, among
other things, fluctuating drug levels, our long-term goal has been to develop nanotechnology-based
drug delivery systems that can improve therapy by more precisely controlling drug concentrations
in target cells. The theme of the current study is to investigate the value of combining AIDS drugs
and modifiers of cellular uptake into macromolecular conjugates having novel pharmacological
properties.
Results:  Bioconjugates were prepared from different combinations of the approved drug,
saquinavir, the antiviral agent, R.I.CK-Tat9, the polymeric carrier, poly(ethylene) glycol and the cell
uptake enhancer, biotin. Anti-HIV activities were measured in MT-2 cells, an HTLV-1-transformed
human lymphoid cell line, infected with HIV-1 strain Vbu 3, while parallel studies were performed
in uninfected cells to determine cellular toxicity. For example, R.I.CK-Tat9 was 60 times more
potent than L-Tat9 while the addition of biotin resulted in a prodrug that was 2850 times more
potent than L-Tat9. Flow cytometry and confocal microscopy studies suggest that variations in
intracellular uptake and intracellular localization, as well as synergistic inhibitory effects of SQV and
Tat peptides, contributed to the unexpected and substantial differences in antiviral activity.
Conclusion: Our results demonstrate that highly potent nanoscale multi-drug conjugates with low
non-specific toxicity can be produced by combining moieties with anti-HIV agents for different
targets onto macromolecules having improved delivery properties.
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Background
Most current anti-Acquired Immunodeficiency Syndrome
(AIDS) drugs target two key enzymes in the human
immunodeficiency virus-1 (HIV-1) replication cycle,
reverse transcriptase and protease. While the remarkable
efficacy of protease and reverse transcriptase inhibitor
combinations for the treatment of HIV-1 infection has
been clearly established in vitro and in the clinic, not even
a single AIDS patient has ever been cured. Accordingly,
new anti-HIV drug candidates having alternate mecha-
nisms of action are under investigation. For example,
ALX40-4C [1,2] blocks viral coreceptor CXCR4 and TAK-
779 [3] blocks coreceptor CCR5. T-20 [4,5] and T-1249
[6-8] inhibit virus-cell fusion by binding to the viral enve-
lope glycoprotein gp-41. Tat antagonists [9,10] interrupt
viral transcription. NCp7 inhibitors [11] hamper viral
assembly and budding. To date, combination pharmaco-
therapy remains the most effective strategy for reducing
viral loads in HIV-infected patients. However, given the
variety of new chemical entities under development, com-
bination therapies hold even greater future promise.
A major impediment to successful anti-HIV-1 therapy is
the emergence of drug resistant strains harboring muta-
tions in genes encoding these viral enzymes [12]. Factors
that are known or expected to contribute to the failure of
highly active antiretroviral therapy (HAART) include pre-
existing resistance [13], low and fluctuating drug concen-
trations due to poor drug absorption or patient non-com-
pliance[6,14,15], and the presence of viral reservoirs and
sanctuary sites [16]. Other mechanisms of resistance are
becoming increasingly recognized in AIDS therapy. For
example, drug-induced biopharmaceutical "resistance"
(i.e., multidrug resistance), an established concept in can-
cer pharmacotherapy [17,18], occurs when the upregula-
tion of cell efflux transporter activity results in lower
cellular exposure and decreased drug efficacy. Therefore,
the ability to control blood and cellular drug concentra-
tions is critical for managing the emergence of classical
viral and multidrug resistance.
Recent successes with HIV peptide fusion inhibitors such
as T20 (e.g., enfuvirtide and fuzeon) [8] suggest that small
anti-HIV peptides can provide clinical utility comple-
menting the antiviral activity of reverse transcriptase or
protease inhibitors. However, many of these peptide
drugs are poorly absorbed or are rapidly cleared from the
body. HIV-1 encodes a small non-structural protein, Tat
(trans-activator of transcription), which is essential for
transcriptional activation of virally encoded genes. Viruses
with deletion of the Tat-function are non-viable [19]. Effi-
cient replication and gene expression of HIV-1 requires a
specific interaction of the Tat viral protein with the trans-
activation responsive element (TAR), a highly stable stem-
loop RNA structure [20]. The interaction with TAR is
mediated by a nine-amino acid basic domain (RKKRR-
QRRR, residues 49–57) of the Tat protein (Figure 1). This
domain is essential for TAR RNA binding in vivo and is suf-
ficient for TAR recognition in vitro [21]. A Tat-derived
basic arginine-rich peptide alone binds TAR RNA with
high affinity in vitro [9]. A peptidyl compound, N-acetyl-
RKKRRQRRR-(biotin)-NH2, containing the 9-amino acid
sequence of Tat protein basic domain, was shown to
inhibit both Tat-TAR interaction in vitro and HIV-1 repli-
cation in cell culture [9]. In addition to the TAR RNA inter-
action, the basic domain in Tat has at least three other
functional properties. It constitutes a nuclear/nucleolar
localization signal [22,23]. The basic Tat peptide is also a
prototypic cell penetrating peptide that can bring a cargo
molecule across the plasma membrane. This was origi-
nally discovered when it was observed that Tat protein
could freely enter cells [24]. Small Tat peptides derived
Table 1: Anti-HIV activity (EC50) and cytotoxicity(LC50) data of R.I.CK-Tat9 based bioconjugates in MT-2 cell culture infected with 
HIV-1 strain LAV-Vbu3 (MOI of 0.01)a.
Compound Number EC50 (µM) Rb LC50 (µM) Therapeutic Index 
(LC50/EC50)
L-Tat9 - 51.3 - 53.8 1
R.I.CK-Tat9 1 0.85 - 29.8 35
R.I.CK(biotin)-Tat9 2 0.018 0.02 46.8 2600
PEG10 K-(R.I.CK-
Tat9)8
8 1.47 1.7 29.1 20
PEG10 K-
(R.I.CK(biotin)-Tat9)8
9 1.50 1.8 29.7 20
SQV(MeSO3H) 
(control)
12 0.015 - 25 1667
SQV-Cys-PEG3.4 K 14 0.90 60 4.5 50
SQV-Cys(R.I.CK-
Tat9)-PEG3.4 K
15 0.015 1 12.5 833
a R is the ratio of the EC50 of the bioconjugate to that of its parent drugs R.I.CK-Tat9 or SQV.
b Several assays of each compound were done with variations in the virus stock, dosage and days of incubation.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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from the basic domain have also been shown to inhibit
HIV replication in cultured T-cells by interacting with the
HIV CXCR4 co-receptor present on the surface of T cells,
thereby blocking infection by T-tropic HIV-1 strains [25-
27]. These peptides may also have translational effects
[28].
Therefore, we have been investigating Tat peptides as ther-
apeutic agents [9,28]. Considering the pleiotrophic effects
of Tat domain peptides, it is not clear whether the delivery
of these peptides to extracellular or intracellular targets or
both is important for their antiviral effect. Furthermore,
since these Tat peptides have cell penetrating activity [29],
they can also potentially be used to enhance the cellular
uptake of an appended drug[30]. However, Tat peptides
have certain disadvantages, such as high systemic clear-
ance due to in vivo degradation, non-specific binding to
other biological components, and rapid renal clearance
due to their low molecular weight and positive charges
[31]. A variety of different strategies have improved biop-
harmaceutical properties of peptide drugs. In our studies,
we have utilized retro-inverso (RI) peptides and macro-
molecular PEG conjugates to overcome the many biop-
harmaceutical challenges faced by Tat peptides. R.I.CK
(retro-inverso-D-cysteine-lysine)-Tat9, N-acetyl-ckrrrqr-
rkkr-NH2, consists of D-amino acids assembled in the
reverse order of the natural L-amino acid Tat9 peptide, N-
acetyl-RKKRRQRRR-NH2. Thus, R.I.CK-Tat9 has a similar
shape and charge distribution to the natural L-amino acid
peptide but is more stable to proteases and retains phar-
macological activity [32]. PEGylation has been shown to
be one of the most successful techniques for improving
the pharmacokinetic and pharmacodynamic properties of
peptide drugs by increasing stability and reducing renal
clearance and protein binding [33].
The second agent used in this study, saquinavir (SQV) was
the first HIV-protease inhibitor approved by the U.S. Food
and Drug Administration. Its structure mimics the pheny-
lalanine-proline cleavage sequence at positions 167 and
168 of the HIV gag-pol polyprotein [34]. Thus, SQV pre-
vents cleavage of gag and gag-pol protein precursors by
HIV protease in acutely and chronically infected cells,
arresting maturation and blocking nascent virions from
becoming infectious [35]. However, therapeutic use of
SQV suffers from problems of low absorptive and high
secretory permeability, bioconversion to inactive metabo-
lites, and poor solubility [36,37]. The oral bioavailability
of SQV in clinical formulations is low and/or variable
with limited penetration into the lymphatic and central
nervous systems (CNS) [38,39]. While its low and varia-
ble bioavailability is primarily attributed to metabolism
by cytochrome P-450 3A, recent results published by our
group [40] and others [41] suggest that multiple mem-
brane transporters may also contribute significantly to the
delivery problems of SQV.
In a previous report [42], we showed that the activity of
SQV prodrug conjugates was reduced when SQV was con-
jugated to PEG3.4 K, compared to the maximal achievable
antiviral efficacy. But activity was restored by the addition
of R.I.CK-Tat9 to the conjugate (EC50 = 15 nM). However,
the mechanism of enhancement for the SQV-PEG3.4 K-
R.I.CK-Tat9 conjugates was not clearly established since,
in addition to targeting intracellular TAR, Tat possesses
cell penetrating properties [29,30] that may promote con-
jugate uptake into the cell and/or it may exert anti-HIV-1
activity by means of cell surface binding to CXCR-4 recep-
tors [25-27]. In the current study, the preclinical in vitro
effectiveness of a small peptidic Tat antagonist, R.I.CK-
Tat9, alone or in combination with saquinavir on multi-
functional poly(ethylene glycol) (PEG)-based bioconju-
gates is demonstrated. Furthermore, the mechanism of
Schematic representation of Tat peptide, the basic domain in the viral Tat protein containing residue 49–57 Figure 1
Schematic representation of Tat peptide, the basic domain in the viral Tat protein containing residue 49–57.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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enhanced activity of the SQV-PEG3.4 K-R.I.CK-Tat9 conju-
gates was addressed by flow cytometry and confocal
microscopy. The current results suggest that the increased
anti-HIV activity of SQV-PEG3.4 K-R.I.CK-Tat9 is due to the
enhanced intracellular uptake and synergistic inhibitory
effects of SQV on HIV protease and Tat peptides on both
CXCR4 co-receptor interaction and/or HIV-1 transcrip-
tional activation.
Results
Synthesis of R.I.CK-Tat9 and SQV conjugates
A series of R.I.CK-Tat9 and SQV bioconjugates was syn-
thesized and characterized. The peptides, L-Tat9, R.I.CK-
Tat9, R.I.CK(biotin)-Tat9, and R.I.CK(ε-carboxyfluores-
cein)-Tat9 (Figure 2) were synthesized, purified and their
structures were confirmed by electrospray ionization mass
spectrometry (ESI-MS). For R.I.CK-Tat9 PEG bioconju-
gates, the thiol group of the cysteine residue at the N-ter-
minus of R.I.CK-Tat9 or its derivatives was linked to the
maleimide group on mPEG-MAL (Figure 3A) or amino
groups of branched 8-arm PEG10 K-(NH2)8 through a sta-
ble thioether bond using a heterobifunctional cross-linker
N-maleimidobutyryloxysuccinimide ester (GMBS) (Fig-
ure 3B). As a control, the eight amino groups of 8-arm
PEG amine were reacted with carboxyfluorescein-NHS
and yielded PEG10 K-(ε-carboxyfluorescein)8 lacking Tat
peptides. These bioconjugates were purified using size-
exclusion chromatography on a Sephacryl S-100 column.
The formation of each bioconjugate was confirmed by
MALDI-TOF mass spectrometry and the concentration of
each bioconjugates was determined by quantitative
amino acid analysis. The overall design for all SQV conju-
Schematic representation of R.I.CK-Tat9 and its derivatives Figure 2
Schematic representation of R.I.CK-Tat9 and its derivatives.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
Page 5 of 15
(page number not for citation purposes)
gates was to link the various components using covalent
bonds that varied in their stability properties (Figure 4). A
biodegradable ester bond was made between the hydroxyl
group of SQV and the carboxyl group of Cys. The esterifi-
cation of the hydroxyl of SQV was confirmed by ESI-MS
and 1H and 13C NMR. The thiol group of Cys was used to
attach R.I.CK-Tat9 and its derivatives via a reducible
disulfide bond, while the amino group of Cys was used to
attach PEG3.4 k via a more stable amide bond. The thiol
group of the cysteine in PEGylated form of SQV-Cys-ester
was activated with 2,2'-dithiodipyridine. Then, disulfide
bond formation resulted from addition of R.I.CK-Tat9 to
the activated PEGylated form of SQV [SQV-Cys(PEG3.4
k)(TP)], giving SQV-Cys(PEG3.4 k)(R.I.CK-Tat9), in 65%
yield after gel permeation purification. Mass spectrometry
using MALDI-TOF of these products demonstrated peaks
at the expected molecular weights.
Stability studies
The stability of the covalent linkages attaching pharma-
cophores to the conjugates was determined. R.I.CK-Tat9
was linked to PEG10 K using a relatively stable thioether
bond. The stability of this bond was assessed by incubat-
ing PEG10 K-[R.I.CK(fluorescein)-Tat9]8 bioconjugates in
PBS (pH 7.4), spiked plasma or PBS (pH 7.4) with 5 µM
reduced glutathione (GSH) at 37°C. Aliquots were with-
drawn at different time points and centrifuged at 14,000 ×
g for 90 min with a 10 kDa cut-off Microcon™ filter. The
conjugated R.I.CK(fluorescein)-Tat9 was retained in the
filter as retentates and separated from the cleaved free
R.I.CK(fluorescein)-Tat9 that passed through the filter.
Synthetic scheme of Tat-PEG bioconjugates with single (3A) or multiple copies (3B) of R.I.CK-Tat9 and fluorescein-labelled  control PEG lacking Tat peptides Figure 3
Synthetic scheme of Tat-PEG bioconjugates with single (3A) or multiple copies (3B) of R.I.CK-Tat9 and fluorescein-labelled 
control PEG lacking Tat peptides.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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Thereafter, the fluorescence of conjugated R.I.CK(fluores-
cein)-Tat9 was measured using a Tecan fluorescence
microplate reader with an excitation wavelength at 485
nm and an emission wavelength at 535 nm. This method
was used rather than measuring fluorescence in the flow-
through, since the concentration of cleaved R.I.CK(fluo-
rescein)-Tat9 could not be quantified due a high degree of
adsorption caused by its positive charges (unpublished
data). The calibration curves of fluorescein-labeled
R.I.CK-Tat9 in PBS (pH 7.4) and in plasma were linear
with correlation coefficients of 0.9993 and 0.9997,
respectively. The concentration of the bioconjugates
decreased with time (Figure 5). Plots of ln [(bioconju-
gate)t] against incubation time (t) were linear within the
concentration range studied indicating that cleavage
occurs by a first order process (Figure 5). The PEG10 k-
[(R.I.CK(fluorescein)-Tat9]8  bioconjugate showed a
longer half-life (t1/2 = 50.6 h) in PBS (pH 7.4) than in
plasma (t1/2 of 24.4 h). The half-life of this bioconjugate
decreased significantly from 50.6 h to 10.5 h in the pres-
ence of 5 µM GSH in PBS (pH 7.4).
SQV was linked to R.I.CK-Tat9 through a SQV-Cys ester
bond. The stability of the ester was evaluated in PBS at pH
7.4 and in spiked plasma, measured at 37°C using a
recently developed fluorogenic protease assay for free SQV
[42]. The release of active SQV was observed with half-
lives of 14 h and 0.9 h in PBS at pH 7.4 and in spiked
plasma, respectively [42].
Biological activity
The anti-HIV activity of each bioconjugate derived from
R.I.CK-Tat9 and SQV was evaluated in vitro in HIV-
infected MT-2 cells (Figure 6) utilizing an established anti-
viral assay [42]. The L-form of Tat9 showed weak anti-HIV
activity (EC50 = 51.3 µM) while the retro-inverso form of
Tat peptide showed much stronger anti-HIV activity (EC50
= 0.85 µM). Biotin appended to the R.I.CK-Tat9 peptide
greatly enhanced the activity of the peptide (EC50 = 0.018
µM), possibly due to the increased cellular uptake (~ 30-
fold) conferred by biotin [43]. The conjugation with a 10
kDa branched PEG might be expected to enhance the sta-
bility of the peptide by protecting it from attack by pepti-
dases, even though the unnatural D-amino acids in the
R.I. peptides may already confer ample protease-resist-
ance. We found that R.I.CK-Tat9 is released from PEG10 k-
(R.I.CK-Tat9)8 conjugates very slowly (t1/2 = 50.6 h) and
that most of the fluorescence labeled PEG10k-(R.I.CK-
Tat9)8 conjugate remained bound to the MT-2 cell surface
rather than being internalized (Figures 7 &8). Thus, the
PEG conjugates of R.I.CK-Tat9 and R.I.CK(biotin)-Tat9
both displayed similar antiviral activity with EC50 of 1.47
Synthetic scheme of Tat-SQV bioconjugates (i) 3 equivalents Fmoc-Cys(S-Trt)-COOH in CH2Cl2 with DIPC/DMAP; (ii) 20%  piperidine in CH2Cl2 ; (iii) TFA/CH2Cl2 (1:1); (iv) 2 equivalents Fmoc-PEG3.4 K-NHS in CH2Cl2 with DIEA; (v) 2 equivalents 2,2'- Dithiodipyridine in DMSO; (vi) 2 equivalents. R.I.CK-Tat9 in DMSO Figure 4
Synthetic scheme of Tat-SQV bioconjugates (i) 3 equivalents Fmoc-Cys(S-Trt)-COOH in CH2Cl2 with DIPC/DMAP; (ii) 20% 
piperidine in CH2Cl2 ; (iii) TFA/CH2Cl2 (1:1); (iv) 2 equivalents Fmoc-PEG3.4 K-NHS in CH2Cl2 with DIEA; (v) 2 equivalents 2,2'-
Dithiodipyridine in DMSO; (vi) 2 equivalents. R.I.CK-Tat9 in DMSO.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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µM and 1.5 µM, respectively, which was weaker than that
of the non-PEGylated forms (Figure 6 and Table 1). This
result suggests that the intracellular inhibitory effect of Tat
peptide may be quantitatively more important than the
extracellular blocking of HIV infection previously
described for Tat-based peptides, although targeting cell
surface receptors might still be an important secondary
mechanism of viral inhibition by either biotinylated or
non-biotinylated peptides.
The activity of SQV in drug conjugates compared to the
maximal achievable antiviral efficacy of free SQV (EC50 =
15 nM) was reduced with addition of PEG3.4 k alone (EC50
= 900 nM), but restored with the addition of R.I.CK-Tat9
to the SQV-PEG3.4 k conjugate (EC50 = 0.015 µM), the
same in vitro potency as free SQV.
The cytotoxicities of the R.I.CK-Tat9 and SQV bioconju-
gates were measured by incubating non-infected MT-2
cells in the presence of different concentrations of the bio-
conjugates for 5 days at 37°C. The cytotoxicity (LC50) of
all the tested bioconjugates was in the low micromolar
range (12.5 – 46.8 µM). The L-form of Tat9 showed the
poorest therapeutic index with essentially equivalent EC50
and LC50. In contrast, a number of the multi-component
bioconjugate molecules such as R.I.CK(biotin)-Tat9 and
SQV-PEG3.4 k-R.I.CK-Tat9 exhibited very favorable thera-
peutic indices of 2600 and 833, respectively. The ratios of
LC50/EC50(i.e., in vitro therapeutic index) are shown in
Table 1.
Flow cytometry and confocal microscopy
Flow cytometry (Figure 7) showed that MT2 cells incu-
bated with fluorescein-labeled control PEG lacking Tat
peptides had a low fluorescence and no cell-associated
fluorescence by fluorescence microscopy (data not
shown), indicating PEG did not bind or enter the cells. In
contrast, cells incubated with 1 µM (concentrations of
conjugates containing Tat9 are indicated in Tat9 equiva-
lents) R.I.CK(fluorescein)-Tat9, PEG3.4 k-R.I.CK(fluores-
cein)-Tat9, or PEG10 k- [R.I.CK(fluorescein)-Tat9]8  had
significant amounts of total cell-associated fluorescence,
with cells incubated with PEG3.4 k-R.I.CK(fluorescein)-
Tat9 and PEG10 k- [R.I.CK(fluorescein)-Tat9]8 having twice
as much fluorescence as cells incubated with R.I.CK(fluo-
rescein)-Tat9. When the cell surface-bound fluorescence
was quenched with trypan blue, 93.8 % of the total cell-
associated fluorescence was intracellular in cells incu-
bated with R.I.CK(fluorescein)-Tat9, 53.6 % of total in
cells incubated with PEG3.4 k-R.I.CK(fluorescein)-Tat9,
and only 19 % in cells incubated with PEG10 k-
[(R.I.CK(fluorescein)-Tat9]8. Since it is known that
arginine-rich peptides bind to CXCR4, this suggests that
multivalent Tat9 binding to CXCR4 on the cell surface
impedes conjugate internalization.
Confocal microscopy studies (Figure 8) showed that in
cells incubated with 1 µM R.I.CK(fluorescein)-Tat9 or
PEG3.4 k-R.I.CK(fluorescein)-Tat9, there was significantly
higher fluorescence intracellularly than on the cell surface.
On the other hand, cells incubated with PEG10 k-
[R.I.CK(fluorescein)-Tat9]8 showed primarily cell surface
bound fluorescence. Note that in Figure 8, only a middle
section of the cells is presented for each compound and
the nucleus-cytosol boundaries of some cells can be dis-
cerned in the DIC (differential interference contrast)
images. This result is consistent with the results from flow
cytometry.
Panel A: Release of R.I.CK(fluorescein)-Tat9 from PEG10 K- [(R.I.CK(fluorescein)-Tat9]8 in PBS (pH 7.4) (■ ), in plasma  (▲ ) or PBS (pH 7.4) with 5µM GSH (▼ ) at 37°C respectively,  using fluorescence detection at excitation wavelength 485  nm and emission wavelength 535 nm Figure 5
Panel A: Release of R.I.CK(fluorescein)-Tat9 from PEG10 K-
[(R.I.CK(fluorescein)-Tat9]8 in PBS (pH 7.4) (■ ), in plasma 
(▲ ) or PBS (pH 7.4) with 5µM GSH (▼ ) at 37°C respectively, 
using fluorescence detection at excitation wavelength 485 
nm and emission wavelength 535 nm. The concentrations of 
the bioconjugates were determined from fluorescence cali-
bration curves that were established in the same media. All 
measurements were done in duplicates. Panel B: Plot of 
ln(bioconjugate)t versus incubation time (t) of the PEG- 
[R.I.CK(fluorescein)-Tat9]8 in PBS (pH 7.4) (■ ), in plasma 
(▲ ) or PBS (pH 7.4) with 5 µM GSH (▼ ) at 37°C respec-
tively. The rate constant (k) is the slope of this linear plot. 
The half-lives (t1/2) for the thioether bond cleavage were cal-
culated using the relation t1/2 = 0.693/k.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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Since the targets of both SQV (HIV-1 protease) and one of
the Tat targets (HIV-1 mRNA TAR region) are in the
cytosol/nucleus compartment and since flow cytometry
and the confocal data shown in Figure 8 do not distin-
guish between the cytosol/nucleus and endosome com-
partments for the intracellular fluorescence, we incubated
cells with either R.I.CK(fluorescein)-Tat9 or PEG3.4 k-
R.I.CK(fluorescein)-Tat9 and a fluid phase endocytosis
marker, tetramethylrhodamine-labeled dextran (10 kDa).
The results (Figure 9) showed that at a relatively high con-
centration (7µM) R.I.CK(fluorescein)-Tat9 or PEG3.4 k-
R.I.CK(fluorescein)-Tat9 (green) were mainly co-localized
with the fluid phase endocytosis marker rhodamine-dex-
tran (red) in punctate dots (orange/yellow in the merged
panels, Figure 9D &9H), suggesting predominant endo-
somal location. Only in cells incubated with R.I.CK(fluo-
rescein)-Tat9, was there some faint green fluorescence that
was not co-localized with the fluid phase endocytosis
marker (arrows in Figure 9D), suggesting some cytosolic
location.
Overall, the confocal data are consistent with the conclu-
sion from flow cytometry analysis that the majority of
R.I.CK-Tat9 is within cells, the majority of PEG10 k-
(R.I.CK-Tat9)8 is on the cell surface, and PEG3.4 k-R.I.CK-
Tat9 is roughly equally distributed between cell surface
and intracellular locales. The confocal data further suggest
that after exposure to 1µM conjugate, intracellular R.I.CK-
Tat9 and PEG3.4 k-R.I.CK-Tat9 are all predominantly
within endosomes. Since the cytosol/nucleus compart-
Representative data from MTT assays showing the anti-HIV activity (EC50) of Tat and SQV compounds using MT-2 cells  infected with HIV-1 strain Vbu 3 at 0.01 MOI Figure 6
Representative data from MTT assays showing the anti-HIV activity (EC50) of Tat and SQV compounds using MT-2 cells 
infected with HIV-1 strain Vbu 3 at 0.01 MOI. Cytotoxiciy (LC50) was determined usjng uninfected cells. [TB: R.I.CK(biotin)-
Tat9, TP: PEG10k-(R.I.CK-Tat9)8, TBP: PEG10 K-(R.I.CK(biotin)-Tat9)8, SQV: saquinavir, SP: SQV-Cys- PEG3.4 K, SPT: SQV- 
PEG3.4 K-R.I.CK-Tat9]AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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ment accounts for the vast majority of cellular volume,
any R.I.CK-Tat9 and PEG3.4 k-R.I.CK-Tat9 molecules that
escaped from endosome, or entered cytosol directly from
outside cell, would be diluted. As a result, the detection of
cytosolic fluorescence is not sensitive and we cannot rule
out the presence in cytosol/nucleus compartment of a
fraction of total intracellular R.I.CK-Tat9 and PEG3.4 k-
R.I.CK-Tat9. Therefore, the potent anti-HIV-1 activity of
SQV-PEG3.4 k-R.I.CK-Tat9 due to addition of the R.I.CK-
Tat9 moiety could be attributable to a variety of factors
including the inhibitory effect of Tat9 peptide on viral
interaction with co-receptor CXCR4 and/or on HIV-1
transcriptional activation, either of which might be syner-
gistic with SQV inhibition of HIV protease.
Discussion
While recent advances in anti-AIDS therapeutics have
resulted in the introduction of more potent drugs, a cure
for HIV infection remains an elusive goal. Many factors
contribute to the inability of current therapeutic regimens
to cure HIV infection. However, central to the problem is
the variability of drug concentrations in the blood and tar-
get tissues resulting from poor patient adherence to com-
plicated regimens, the inability of these potent agents to
selectively target infected tissues, and the poor penetra-
tion or retention of drugs in reservoir and sanctuary sites.
It is becoming more obvious that better drug delivery and
targeting technologies are required to increase total body
persistence, target cell exposure and retention of these
potent therapeutic agents. In the current study, we have
produced and tested the first of a series of nanoscale drug
delivery vehicles in order to better target HIV infected cells
and possibly to provide novel modes of action.
The present report describes the design, synthesis and ini-
tial characterization of a series of PEG-based bioconju-
gates in order to achieve maximum therapeutic payload of
Tat peptide, to explore multi-drug delivery on one biocon-
jugate and to determine the potential role of Tat in the cel-
lular uptake and HIV inhibition by the conjugates. These
bioconjugates were designed (i) to carry multiple copies
of the R.I.CK-Tat9 drug linked by stable thioether bonds
to 8-arm poly(ethylene) glycol (PEG), (ii) to carry multi-
ple drugs such as SQV for combination therapy, (iii) to
have an extended biological and chemical half-life, (iv) to
selectively release appended drug molecules inside the cell
because of the differential in reducing capacity between
blood and the internal cell environment and finally, (v) to
enhance cellular uptake of the drug and bioconjugate
through the use of uptake enhancing moieties like biotin
attached to the R.I.CK-Tat9. These modifications were
designed to increase the therapeutic peptide's bioavaila-
bility, biodistribution and delivery into HIV sanctuary
sites of both the therapeutic Tat peptide and appended
drugs, exemplified here by SQV.
The current study is aimed at improving the therapeutic
potential of a Tat-antagonistic compound R.I.CK-Tat9. It
is an analog of the nine amino acid sequence of the TAR-
binding basic domain of Tat protein in which the direc-
tion (polarity) of the amino acid sequence is reversed and
the chirality of each amino acid residue is inverted from L
to D. Retro-inverso analog peptides are expected to have
shapes and charge distributions of their side chains simi-
lar to the natural L-amino acid peptides, but are highly
resistant to proteolysis [44,45]. Furthermore, Wender et.
al. found that the L-, D- and R.I. forms of Tat9 showed
similar cellular uptake in serum-free medium, while in the
presence of serum the D-form was modestly more active
and the R.I. form much more active than the L-form, indi-
cating the likely role of proteolysis in limiting the activity
of natural peptides [46]. The current results show that
R.I.CK-Tat9 had a 60-fold higher anti-HIV activity than L-
Tat9, consistent with the enhanced stability and/or
increased intracellular availability of R.I.CK-Tat9.
Choudhury et al. showed that Tat9-C(biotin) with S-bioti-
nylation of the cysteine residue was taken up 30-fold
more efficiently by Jurkat cells than was unbiotinylated
Tat9-C (3% versus 0.1%, respectively) [9]. This was attrib-
uted to increased hydrophobic interactions with the
plasma membrane [43] and it was hypothesized that
Quantitative data from flow cytometry showing the intracel- lular fluorescence and cell surface bound fluorescence of flu- orescein-labeled PEG10 K [PEG-(fluo)8], R.I.CK-Tat9 (R.I.  Tat9), PEG3.4 K-R.I.CK-Tat9 (PEG-Tat), and PEG10 K-(R.I.CK- Tat9)8 [PEG-(Tat)8] after 24 hrs incubation with MT-2 cells  at 37°C for 24 hrs Figure 7
Quantitative data from flow cytometry showing the intracel-
lular fluorescence and cell surface bound fluorescence of flu-
orescein-labeled PEG10 K [PEG-(fluo)8], R.I.CK-Tat9 (R.I. 
Tat9), PEG3.4 K-R.I.CK-Tat9 (PEG-Tat), and PEG10 K-(R.I.CK-
Tat9)8 [PEG-(Tat)8] after 24 hrs incubation with MT-2 cells 
at 37°C for 24 hrs. The total cell associated fluorescence was 
quantified by flow cytometry. The intracellular fluorescence 
was measured after the cell surface-bound fluorescence was 
quenched by 0.2 mg/ml trypan blue at pH 5.8. The cell sur-
face bound fluorescence is the difference between the total 
cell associated fluorescence and the intracellular fluores-
cence.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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biotinylation would result in enhanced inhibiton of trans-
activating activity by the biotinylated compound. The cur-
rent results confirm this hypothesis since the biotinylated
RI-Tat9 was 47 times more potent than the RI-Tat9 and
was approximately as potent as SQV in inhibiting HIV-1.
The central hypothesis of the current study is that
improved delivery would result in an enhancement in the
pharmacological properties of Tat inhibitors, in particular
R.I.CK-Tat9. Thus, it was anticipated that PEGylation of
R.I.CK-Tat9 would enhance the pharmacological proper-
ties in vivo for more effective delivery. The PEG residues
were chosen to avoid in vivo binding of R.I.CK-Tat9 to
plasma proteins and rapid elimination from the blood
[47]. Thus, PEGylation provides a way to increase the sta-
bility and body persistence of the R.I.CK-Tat9, which
could result higher in vivo activity. However, the PEG con-
jugates reduced the antiviral activity of R.I.CK-Tat9 or
R.I.CK(biotin)-Tat9 in cell culture experiments (Table 1).
The thioether bonds, used in the linkage between R.I.CK-
Tat9 or R.I.CK(biotin)-Tat9 and PEG were very stable,
insuring that Tat was not released from the conjugate.
These results suggest the quantitatively more important
antiviral effect of R.I.CK-Tat9 depends upon its release
from PEG, presumably reflecting a requirement for entry
into infected cells.
An oligocationic peptide compound (ALX40-4C),
designed to mimic the basic domain of the HIV-1 Tat [2],
was also found to interfere with viral entry through the
inhibition of the chemokine receptor CXCR4 on the host
cell membrane [1]. The blocking of viral entry resulted in
a more potent response than the inhibition of transactiva-
tion by that compound [2]. To delineate whether the anti-
viral mechanism of the R.I.CK-Tat9 conjugates is by inhi-
bition of transactivation or by blocking of cell surface co-
receptor, R.I.CK-Tat9 was labelled with the fluorescence
tag carboxyfluorescein-NHS and conjugated to PEG3.4 K
and PEG10 K for stability and uptake mechanism studies of
the final conjugates. Flow cytometry showed 93.8%,
53.6%, and 19.0% of total cell-associated R.I.CK(fluores-
cein)-Tat9, PEG3.4 K-R.I.CK(fluorescein)-Tat9, and PEG10
K- [R.I.CK(fluorescein)-Tat9]8, respectively, were within
the cells. In contrast, the control fluorescein labelled PEG
lacking the Tat peptide, PEG10 K-(fluorescein)8, showed
little cell association by flow cytometry and no cell surface
binding by fluorescence microscopy (data not shown).
The confocal microscopy studies showed that cells incu-
bated with 1µM R.I.CK(fluorescein)-Tat9 or PEG3.4 K-
R.I.CK(fluorescein)-Tat9 showed significant higher intrac-
ellular fluorescence, while cells incubated with PEG10 K-
[R.I.CK(fluorescein)-Tat9]8 showed primarily cell surface-
associated fluorescence. These results suggested that the
observed anti-HIV activity of the uncleavable PEG10 K-
(R.I.CK-Tat9)8 conjugates is a result of the binding of the
conjugate to cell surface CXCR4 receptor, which is consist-
ent with observations of other groups [1,2]. However, the
reduced potency of the conjugates relative to free R.I.CK-
Tat9 suggests that this peptide may have more anti-HIV-1
activity at intracellular sites than at the cell surface. These
results support the model that the most potent mecha-
nism of action of this peptide agent is inhibition of the
transcriptional effects of the viral Tat protein.
While expected to be a stronger binder to CXCR4, PEG10
K-(R.I.CK-Tat9)8 is less promising than PEG3.4 K-R.I.CK-
Tat9 in intracellular targeting. The intracellular space con-
sists of two topological compartments – the cytosol/
nucleus and all membrane-bound organelles including
endosomes and lysosomes. HIV-1 protease and reverse
transcriptase, the cellular targets of the majority of current
anti-HIV-1 drugs, are located in the cytosol, whereas the
TAR region of all HIV-1 mRNA transcripts, the cellular tar-
get of both conjugates and their released R.I.CK-Tat9, is
located in the nucleus. Compared to PEG3.4 K-R.I.CK-Tat9,
less PEG10 K-(R.I.CK-Tat9)8 is internalized. Significant por-
tions of both internalized conjugates are within endo-
somes. Unless they escape, endosome-confined
conjugates and their drug-carrying derivatives cannot
reach these cellular targets. At present, there is some evi-
dence in the literature for the endosomal escape of Tat
peptide-conjugates or fusion proteins. We recently discov-
ered a possible pH-dependent endosomal escape mecha-
nism that could operate at the mildly acidic pH of 6.5 of
Confocal microscopic images of suspended MT-2 cells incu- bated with R.I.CK(fluorescein)-Tat9 (A, B), PEG3.4 K- R.I.CK(fluorescein)-Tat9 (C, D) and PEG10 K- [R.I.CK(fluores- cein)-Tat9]8 (E, F) for 24 hours (all 1µM relative to Tat9) Figure 8
Confocal microscopic images of suspended MT-2 cells incu-
bated with R.I.CK(fluorescein)-Tat9 (A, B), PEG3.4 K-
R.I.CK(fluorescein)-Tat9 (C, D) and PEG10 K- [R.I.CK(fluores-
cein)-Tat9]8 (E, F) for 24 hours (all 1µM relative to Tat9). (A, 
C and E show fluorescence images while B, D and F are light 
images generated by differential interference contrast (DIC) 
of the same fields. All focal planes are through the middle of 
the cells. A and C show bright intracellular fluorescence, 
while E shows primarily cell surface bound fluorescence.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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early endosomes (to be published). Once they escape
from endosomes, both conjugates and their released
R.I.CK-Tat9 must enter the nucleus in order to meet their
TAR target. The cytosol and the nucleus are continuous
through nuclear pores, which have a functional diameter
of about 40 nm. This pore size roughly equals the effective
size of a linear PEG molecule of 20 kDa [48], implying
that the 25 kDa PEG10 K-(R.I.CK-Tat9)8 might not be able
to enter the nucleus while the 5 kDa PEG3.4 K-R.I.CK-Tat9
might.
In this study, we used uninfected MT2 cells that are trans-
formed CD4+ T cells, which are capable of supporting
HIV-1 replication. Depending on a particular anti-HIV-1
agent tested and the MOI (multiplicity of infection) used,
MT2 cells can serve as a useful model for HIV-1 infected or
uninfected T cells in vivo. Critical to current HAART regi-
mens is that both infected and uninfected T cells should
be adequately loaded with anti-HIV-1 drugs at all times.
In the infected cells, the drugs prevent the production of
mature, infectious viruses. In the uninfected cells, the
drugs play a prophylactic role, ensuring abortive infection
or replication whenever infection occurs. Constant new
HIV-1 infection must take place as both HIV-1 and virus-
replicating T cells have short in vivo half-life yet the virus
keeps evolving and cessation of HAART inevitably leads to
viral load rebounding. We now know that during all
stages of HIV disease CD4+ T cell depletion occurs pre-
dominantly in the gut [49].
Certain aspects of the performance of PEG conjugates
(e.g., plasma persistence and protein binding) can only be
studied in vivo and are not addressed in the current study.
The known in vivo advantages of PEGylation of various
pharmacophores indicates the potential that PEG-based
bioconjugates could display useful therapeutic properties
of increased plasma half-life [50], lower cytotoxicity [51],
and reduced protein binding, which could outweigh the
observed reduction in efficacy seen in this study for some
PEGylated drugs. This will require further future study in
in vivo models and is beyond the scope of the current stud-
ies.
Multiple-drug cocktail regimens have been associated
with the recent successes in improving the quality of life
of patients with AIDS. However, delivery of drugs to the
bloodstream rather than to many of the known sites of
high viral replication may not insure that the maximal
therapeutic effect will be obtained. A potential first step in
achieving this maximal effect is to better control the expo-
sure of infected cells to multiple therapeutic agents. In this
proof-of-principle study, the prototypical protease inhibi-
tor, SQV, was conjugated to PEG3.4 K and PEG3.4 K-R.I.CK-
Tat9. The conjugation of PEG to SQV yielded a much less
active prodrug conjugate SQV-Cys- PEG3.4 K with EC50 at
900 nM. The 60-fold lower activity of the conjugate com-
pared to the parent drug could be due to the slow cleavage
of the ester bond and/or low cell uptake of the conjugate.
However, the addition of Tat to SQV-Cys- PEG3.4 K
resulted in a conjugate with an EC50 of 0.015µM, the same
in vitro potency as the free SQV. The increased activity of
SQV-PEG3.4 K-R.I.CK-Tat9 may be attributable to a variety
of factors including the enhanced intracellular uptake by
the bifunctional conjugates containing both Tat peptide
and SQV, the synergistic effects of SQV on HIV protease
and Tat peptides on both HIV Tat-TAR binding and/or on
cell surface receptor CXCR4. All of these results suggest
that higher anti-HIV activity was attained mainly due to
the enhanced intracellular uptake of SQV-PEG3.4 K-R.I.CK-
Tat9 resulting in improved delivery of SQV. However, the
synergistic effects of SQV on HIV protease and Tat pep-
tides on both HIV TAR and/or CXCR4 are likely to con-
tribute.
Conclusion
In the current study, the preclinical in vitro effectiveness of
a small peptidic Tat antagonist, R.I.CK-Tat9, alone or with
saquinavir using PEG-based bioconjugates was demon-
strated. While the PEG-linkage alone did not potentiate
the activity of R.I.CK-Tat9, the addition of SQV to R.I.CK-
Tat9-PEG bioconjugates significantly enhanced the anti-
retroviral activity to the level comparable to free SQV.
These bifunctional conjugates were more potent than the
PEG conjugates with R.I.CK-Tat9 or SQV alone. These
results demonstrate that the macromolecular bioconju-
Confocal microscopic images of suspended MT2 cells incu- bated with R.I.CK(fluorescein)-Tat9 (A-D) or PEG3.4 K- R.I.CK(fluorescein)-Tat9 (E-H) in the presence of endocyto- sis marker rhodamine-dextran at 37°C for 24 hours Figure 9
Confocal microscopic images of suspended MT2 cells incu-
bated with R.I.CK(fluorescein)-Tat9 (A-D) or PEG3.4 K-
R.I.CK(fluorescein)-Tat9 (E-H) in the presence of endocyto-
sis marker rhodamine-dextran at 37°C for 24 hours. A and E 
show fluorescein fluorescence (green), B and F are DIC 
images, C and G show rhodamine-dextran (red), and D and 
H show overlaying of the green and red images. Colocaliza-
tion of two dyes (orange-yellowin the overlay images) implies 
endosomal uptake of PEG3.4 K-R.I.CK-Tat9. Cells incubated 
with R.I.CK(fluorescein)-Tat9 showed some faint green fluo-
rescence that was not co-localized with the fluid phase endo-
cytosis marker (arrows in Figure 9D), suggesting some 
cytosolic localization.AIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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gates could deliver drugs to multiple targets, bringing drug
delivery systems down to the molecular level. Since in vitro
studies of anti-HIV activity do not account for factors that
would enhance in vivo potency (e.g., increased body per-
sistence and decreased binding), it is quite possible that
the advantages of SQV-PEG3.4 KR.I.CK-Tat9 conjugates
over the parent drugs could become evident by in vivo test-
ing. In addition, all of the bioconjugates demonstrated
low cytotoxicity.
The modular approach for producing a targeted nanop-
harmaceutical delivery system that we have taken allows
for appending different drug combinations or combina-
tions of drugs and cellular uptake enhancing agents in
order to maximize the therapeutic effect. Therefore PEG
bioconjugates could constitute a powerful delivery system
for either single drug administration or combination ther-
apy. However further mechanistic studies are needed to
optimize the structure (e.g. size, shape and other features)
of the PEG bioconjugates. Additional studies are needed
to assess the potential in vivo benefits (long half-life, lower
clearance rate) of these conjugates.
Methods
Synthesis of R.I.CK-Tat9 and SQV conjugates
R.I.CK-Tat9 and its derivatives, compounds 1–3 (Figure 2)
were synthesized manually on a MBHA Rink amide resin
(Novabiochem, La Jolla, CA) via Fmoc chemistry in the
presence of coupling activating reagents, BOP (benzotria-
zol-1-yl-oxytris(dimethylamino)phosphonium hex-
afluorophosphate) and HOBt (N-hydroxybenzotriazole)
(Sigma-Aldrich, St. Louis, MO). The ε-Dde (1-(4,4-dime-
thyl-2,6-dioxocyclohex-1-ylidene)ethyl) protecting group
(in the N-terminal lysine residue) was selectively removed
using 2 % hydrazine in DMF (dimethylformamide) and
reacted to attach the appended groups biotin-NHS or car-
boxyfluorescein-NHS (Sigma-Aldrich, St. Louis, MO) on
solid support. The peptides were then acetylated, cleaved
and purified on a Vydac C18 column (10 µm, 2.2 × 25 cm,
Vydac, Hesperia, CA) with detection at 220 nm; fluores-
cence of labelled peptides was detected at 535 nm (emis-
sion) and 485 nm (excitation). The purified products were
lyophilized and confirmed by electrospray ionization
mass spectra(ESI-MS).
In the synthesis of R.I.CK-Tat9-PEG bioconjugates (Figure
3), R.I.CK(fluorescein)-Tat9 was conjugated to mPEG-
MAL by the reaction of the thiol group of R.I.CK(fluores-
cein)-Tat9 with the maleimide group on mPEG-MAL (4),
which formed a stable thioether bond between PEG and
R.I.CK(fluorescein)-Tat9. The eight amino groups of
PEG10 K-(NH2)8 (MW 10 kDa, 8-arm branched, Nektar
Therapeutics, Huntsville, AL) (6) were first activated with
three-fold molar excess of the heterobifunctional cross-
linker, N-maleimidobutyryloxysuccinimide ester (GMBS)
(Pierce Biotechnology, Rockford, IL), in DMF to form a
maleimide activated PEG (7). The reaction was stirred
overnight at room temperature. The product was precipi-
tated with cold ether and dried under vacuum to yield the
solid PEGylated product. The GMBS linker essentially
converts a primary amino group to a maleimide group
that can react with a thiol group to form a stable thioether
bond. This activated intermediate 7 was reacted with a
three-fold molar excess of 1, 2 and 3, respectively, with
coupling reagents HOBt (4-fold molar excess) and BOP
(3-fold molar excess) in DMF. DIEA (diisopropylethyl-
amine, 1 % v/v) was added to adjust to neutral pH. For
control, the eight amino groups of 8-arm PEG amine were
reacted with carboxyfluorescein-NHS in the presence of
1%DIEA in DMF to yield 11 PEG10 K-(fluorescein)8 lack-
ing Tat peptides. The products were recrystallized from
cold ether and dried under vacuum overnight. These bio-
conjugates 8–11 were purified using size-exclusion chro-
matography using a Sephacryl S-100 column (Amersham,
Piscataway, NJ) in 0.1 M PBS, pH 7.4, with detection at
220 nm (for 8 and 9). For 10, fluorescence was detected at
535 nm (emission) and 485 nm (excitation). The forma-
tion of the bioconjugates (8–11) was confirmed by
MALDI-TOF mass spectrometry and the concentrations of
bioconjugates were determined by amino acid analysis.
In the synthesis of the SQV conjugates (Figure 4), the
active hydroxyl function of SQV (12, extracted from
Inverase, Roche) was esterified with Fmoc-Cys(S-Trt)-
COOH using DIPC (1,3-diisopropylcarbodiimide)/
DMAP [4-(dimethylamino)pyridine] as coupling reagent.
SQV-Cys ester (13) was obtained with 82% yield after
Fmoc removal with piperidine, followed by TFA(trifluor-
oacetic acid) -deprotection of the Trt (trityl) group. The
esterification of the hydroxyl of SQV after silica gel purifi-
cation was confirmed by ESI-MS and 1H and 13C NMR.
ESI-MS (m/z): 774.5 (M+H)+; 796.5 (M+Na)+. PEGyla-
tion of 13 was carried out using PEG3.4 k-NHS in the pres-
ence of DIEA/DCM to give 14. This product was purified
using gel permeation chromatography (Sephadex LH-20
column in DMF, 239 nm) resulting in 70 % yield. The for-
mation of 14 was confirmed by MALDI-TOF (m/z (%)
3837.6) and 1H and 13C NMR. The thiol group of the
cysteine in PEGylated form of SQV-Cys-ester (14)  was
then activated with 2,2'-dithiodipyridine. Addition of 1 to
the activated PEGylated form of SQV-Cys-ester (14) gave
15 with 65% yield after gel permeation purification. Mass
spectrometry of these products demonstrated peaks at the
expected molecular weights using MALDI-TOF (m/z (%)
5447.6.
Release kinetics of R.I.CK-Tat9 by cleavage of thioether 
bond
The stability of fluorescein-labeled PEG10 k-(R.I.CK-Tat9)8
bioconjugates was investigated in PBS (pH 7.4) and rabbitAIDS Research and Therapy 2006, 3:12 http://www.aidsrestherapy.com/content/3/1/12
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plasma, at 37°C. The stability of the bioconjugates was
also investigated in PBS (pH 7.4) at 37°C by treating them
with 5 µM glutathione (GSH) (Sigma-Aldrich, St. Louis,
MO), a physiologically relevant reducing reagent that is
responsible for intracellular reductive environment inside
cells. Initially, different concentrations (0.01 – 10.0 µM)
of R.I.CK(fluorescein)-Tat9 were dissolved separately in
PBS (pH 7.4) and in plasma and their fluorescence meas-
ured by Tecan fluorescence microplate reader (excitation
at 485 nm, emission at 535 nm) to obtain calibration
curves in PBS (pH 7.4) and in plasma. Thereafter, the bio-
conjugate solutions were incubated separately in PBS (pH
7.4) and in spiked rabbit plasma at 37°C, along with GSH
treated bioconjugates in PBS (pH 7.4) at 37°C. Aliquots
were withdrawn at different time points and centrifuged at
14,000 × g for 90 min with a Microcon™ filter (molecular
weight cut-off = 10,000 Da) (Amicon Inc., Beverly, MA).
The drug moiety cleaved from the bioconjugate during the
incubation passes through the filter whereas the drug
moiety that remains linked to the PEG carrier is retained.
[Note that a PEG polymer of 3,400 Da behaves as a
>10,000 Da peptide on ultrafiltration.] The retentates
resulting from the different incubation time points were
withdrawn and subjected to fluorescence detection. Each
measurement was done in duplicate. The concentrations
of the bioconjugates were determined from a fluorescence
calibration curve that was established in the same media.
The rate constant (k) was obtained from the linear plot of
ln(bioconjugate)t versus incubation time, t (h), where
[bioconjugate]t = concentration of bioconjugate at differ-
ent incubation time, t, (Figure 5). The half-life (t1/2) of the
cleavage of thioether bond from the bioconjugates was
calculated from the relation t1/2 = 0.693/k where k is the
slope of the linear plot.
Release kinetics of SQV by cleavage of ester bond
A fluorogenic protease inhibition assay was used to meas-
ure the hydrolysis kinetics of SQV-Cys ester which was the
common intermediate for all the synthesized R.I.CK-Tat9-
SQV bioconjugates. The chemical stability of this ester was
determined in PBS at pH 7.4 and in spiked plasma both
measured at 37°C as reported earlier [42].
Antiviral assays
The in vitro anti-HIV activity of PEG conjugates was deter-
mined by a MTT-based HIV-1 susceptibility assay reported
previously [42] using MT-2 cells, an HTLV-1-transformed
human T-cell leukemia cell line, infected with the HIV-1
strain LAV-Vbu3. The cytotoxicity of the conjugates was
evaluated in parallel. The MT-2 cells were grown in RPMI
1640 DM (Dutch modification) medium supplemented
with 20% FBS (fetal bovine serum), 1% w/v pen-strep,
and 1% w/v L-glutamine and maintained at 37°C in 5%
CO2 in an incubator. The cultured MT-2 cells were diluted
to 2 × 105 cells/mL and infected at a multiplicity of infec-
tion (MOI) of 0.01 (1 viral particle per 100 cells), causing
the death of 90% of the cells 5 days later. The tested con-
jugates were diluted with RPMI 1640 medium and were
added to the cultured MT-2 cells after viral infection. Each
conjugate was tested in triplicate for its antiviral activity.
Cell viability was measured by the colorimetric MTT test
at 540 nm, which is directly proportional to the number
of living cells. The conjugate EC50 and LC50 values were
determined from the curves of the percentage of viral cell
killing and cytotoxicity against compound concentration
(Table 1, Figure 6).
Confocal microscopy
MT2 cells were treated with fluorescein-labeled R.I.CK-
Tat9 or its conjugates for 24 hours. Where indicated, a
fluid phase endocytosis marker, tetramethylrhodamine-
Dextran/10 kDa (Invitrogen/Molecular Probe), was used
at 0.25 mg/ml in co-incubation with a fluorescein-labeled
compound. All images were taken of live cells on a Leica
TCS SP2 Spectral Confocal Microscope using the XYZ
mode and 0.25 micrometer per section. The fluorescence
wavelength windows for different dyes were well sepa-
rated to ensure no breach-through from one dye to
another.
Flow cytometry
MT-2 cells were grown to 2 days post-confluency and aliq-
uots of 2 × 106 cells were washed briefly and incubated in
96-well microplates with 1 µM PEG10 K, R.I.CK(fluores-
cein)-Tat9, PEG3.4 K-R.I.CK(fluorescein)-Tat9 and PEG10 K-
[R.I.CK(fluorescein)-Tat9]8  bioconjugate for 24 hours.
Trypan blue staining was used for quenching of cell sur-
face bound fluorochrome emission. After the 24 hours
incubation with tested conjugates, the medium was
immediately removed from the wells. Part of the cells
were washed and resuspended in 0.02 M sodium acetate
buffer (pH 5.8). The remaining cells were suspended in
sodium acetate buffer containing 0.2 mg/ml trypan blue.
After 20s, the cells were washed twice and resuspended in
the sodium acetate buffer. The total cell associated fluores-
cence was then analyzed by flow cytometry using a Coul-
ter EPICS PROFILE equipped with a 25 mW argon laser.
For each analysis, 10,000 to 20,000 events were accumu-
lated. The total cell associated fluorescence was the cell
associated fluorescence of cells without quenching by
trypan blue. The intracellular fluorescence was the cell
associated fluorescence of cells quenched by trypan blue.
The cell surface bound fluorescence is the difference
between the total cell associated fluorescence and the
intracellular fluorescence.
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